199 related articles for article (PubMed ID: 28699238)
1. Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Zhang R; Ma M; Dong G; Yao RR; Li JH; Zheng QD; Dong YY; Ma H; Gao DM; Cui JF; Ren ZG; Chen RX
Cancer Sci; 2017 Sep; 108(9):1778-1786. PubMed ID: 28699238
[TBL] [Abstract][Full Text] [Related]
2. Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
Zhang R; Ma M; Lin XH; Liu HH; Chen J; Chen J; Gao DM; Cui JF; Ren ZG; Chen RX
BMC Cancer; 2018 Sep; 18(1):901. PubMed ID: 30227844
[TBL] [Abstract][Full Text] [Related]
3. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
4. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
5. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
Carr BI; Wang Z; Wang M; Cavallini A; D'Alessandro R; Refolo MG
Cancer Biol Ther; 2011 Sep; 12(6):531-8. PubMed ID: 21734462
[TBL] [Abstract][Full Text] [Related]
6. Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition.
Zhang R; Lin XH; Ma M; Chen J; Chen J; Gao DM; Cui JF; Chen RX
J Transl Med; 2018 Nov; 16(1):302. PubMed ID: 30400797
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
9. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
13. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
14. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
Liang Y; Chen J; Yu Q; Ji T; Zhang B; Xu J; Dai Y; Xie Y; Lin H; Liang X; Cai X
Cancer Med; 2017 Dec; 6(12):2787-2795. PubMed ID: 29030911
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
18. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
19. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
20. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
